Treatment of patients with cancer using cystostatics, biologic response modifiers, hormones and other drugs, including peripheral stem cell transplants. Quality of life assessments and patient discriminant analysis form an integral part. Specific clinical reseach is done comparing standard treatments to new, promising treatments (Phase III), as well as new treatments / combinations (Phase II) across the spectrum of malignancies. Co-operative research involving ECOG (USA), EORTC (Europe), Australia, New Zealand and some Middle Eastern and African countries is maintained at a high level and ensures that cutting edge knowledge is rapidly disseminated while state of the art care pervades hand-in-hand with clinical cancer research

Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport BL: 2001. Effect of epoetin alfa on hematologic parameters and quality of of life in cancer patients receiving non platinum chemotherapy: Results of a randomozed, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 19(11) / Jun, pp 2865-2874.

Schink JC, Weller EA, Harris LS, Cella D, Gerstner J, Falkson CI, Wadler S: 2001. Outpatient taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: An Eastern Cooperative Oncology Group Phase II study (E2E93). Cancer Journal, 7(2) / Apr/Mar, pp 155-164.